Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $325.30 million. The enterprise value is $272.69 million.
| Market Cap | 325.30M |
| Enterprise Value | 272.69M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 83.20 million shares outstanding. The number of shares has increased by 116.90% in one year.
| Current Share Class | 83.20M |
| Shares Outstanding | 83.20M |
| Shares Change (YoY) | +116.90% |
| Shares Change (QoQ) | +28.19% |
| Owned by Insiders (%) | 7.07% |
| Owned by Institutions (%) | 59.15% |
| Float | 65.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.17 |
| Forward PS | 26.93 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 27.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.19
| Current Ratio | 12.19 |
| Quick Ratio | 11.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.32 |
Financial Efficiency
Return on equity (ROE) is -4,796.52% and return on invested capital (ROIC) is -70.88%.
| Return on Equity (ROE) | -4,796.52% |
| Return on Assets (ROA) | -48.06% |
| Return on Invested Capital (ROIC) | -70.88% |
| Return on Capital Employed (ROCE) | -59.29% |
| Weighted Average Cost of Capital (WACC) | 7.05% |
| Revenue Per Employee | $352,000 |
| Profits Per Employee | -$3.84M |
| Employee Count | 28 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +243.04% in the last 52 weeks. The beta is 0.58, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +243.04% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 3.62 |
| Relative Strength Index (RSI) | 55.02 |
| Average Volume (20 Days) | 798,564 |
Short Selling Information
The latest short interest is 10.85 million, so 13.04% of the outstanding shares have been sold short.
| Short Interest | 10.85M |
| Short Previous Month | 10.27M |
| Short % of Shares Out | 13.04% |
| Short % of Float | 16.64% |
| Short Ratio (days to cover) | 12.46 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $9.86 million and -$107.61 million in losses. Loss per share was -$1.29.
| Revenue | 9.86M |
| Gross Profit | -28.77M |
| Operating Income | -50.61M |
| Pretax Income | -107.61M |
| Net Income | -107.61M |
| EBITDA | -50.56M |
| EBIT | -50.61M |
| Loss Per Share | -$1.29 |
Balance Sheet
The company has $88.81 million in cash and $36.20 million in debt, with a net cash position of $52.61 million or $0.63 per share.
| Cash & Cash Equivalents | 88.81M |
| Total Debt | 36.20M |
| Net Cash | 52.61M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | -12.99M |
| Book Value Per Share | -0.16 |
| Working Capital | 85.09M |
Cash Flow
| Operating Cash Flow | -40.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 53,000 |
| Net Borrowing | 35.00M |
| Free Cash Flow | -40.67M |
| FCF Per Share | -$0.49 |
Margins
| Gross Margin | -291.85% |
| Operating Margin | -513.47% |
| Pretax Margin | -1,091.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -116.90% |
| Shareholder Yield | -116.90% |
| Earnings Yield | -32.91% |
| FCF Yield | -12.44% |
Analyst Forecast
The average price target for Opus Genetics is $10.61, which is 171.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.61 |
| Price Target Difference | 171.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 45.87% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -3.4 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 2 |